Sapheon Inc., based in Santa Rosa, California, has been acquired by the Irish Covidien plc, a global healthcare products leader dedicated to innovation and long-term growth. Financial details have not been disclosed.
Sapheon Inc. is a medical device company whose mission is to develop new approaches and disruptive technologies for the treatment of vascular disease. The company’s current focus is the VenaSeal Sapheon Closure System, a novel treatment for venous reflux disease. Sapheon, Inc. will operate as a subsidiary of Covidien plc.
Covidien plc develops, manufactures, and sells healthcare products for use in clinical and home settings worldwide. Through its Medical Devices and Medical Supplies segments, the company creates innovative medical solutions for better patient outcomes and delivers value through clinical leadership and excellence.
One of Oaklins' teams in the USA served as the exclusive financial advisor to the seller in this transaction.
© Oaklins. All rights reserved. Oaklins refers to Oaklins International Inc. and/or one of its member firms, each of which is a separate legal entity. Please see www.oaklins.com/legal for further details.